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DCs are critical components of the immune sys-
tem that link its innate and adaptive arms (1). 
Located in tissues and lymphoid organs, DCs 
constantly sample the environment and rec-
ognize any invading pathogens through pat-
tern recognition receptors such as Toll-like 
receptors (TLRs). Pathogen recognition and 
capture triggers DC maturation, which in-
volves the up-regulation of surface MHC class 
II and co-stimulatory molecules, secretion of 
cytokines such as IL-12, and migration into 
T cell areas of lymphoid organs. In addition to 
antigen presentation to T lymphocytes, mature 
DCs recruit and activate multiple cell types, in-
cluding B and NK lymphocytes. In the steady 
state, the DC system comprises resident tissue 
DCs, immature blood-derived DCs in the 
lymphoid organs, and activated DCs migrating 
from the tissues into lymph nodes (2). In addi-
tion to these conventional DCs, plasmacytoid 
DCs (PDCs) represent a distinct DC type spe-
cialized in virus recognition and secretion of 
type I interferons. In the mouse, the integrin 
αL chain CD11c serves as a relatively specifi  c 
DC marker, with conventional DCs and PDCs 
being CD11chigh and CD11clow, respectively.
Conventional blood-derived DCs in lym-
phoid organs comprise two major subsets, distin-
guished in the mouse by the expression of surface 
marker CD8. In addition to the lack of CD8, 
CD8− DCs can be identifi  ed by the expression 
of the myeloid marker CD11b and of a specifi  c 
marker, DC inhibitory receptor 2, recognized by 
mAb 33D1 (3). The development of both CD8− 
and CD8+ DCs in the spleen appears to be dis-
tinct from other organs, with the lineage and 
subset commitment occurring in the recently 
identifi  ed splenic DC progenitors (4). The more 
abundant CD8− DCs reside in the marginal zone 
(MZ) of the splenic lymphoid follicles and pre-
ferentially present exogenous antigens on MHC 
class II proteins (3). On the other hand, CD8+ 
DCs are believed to reside in the T cell zones, al-
though recent studies suggest a broader distribu-
tion in the spleen (5). This DC subset is uniquely 
capable of the cross-presentation of cell-associated 
antigens via the MHC class I pathway (3, 6). Fur-
thermore, a substantial fraction of genes diff  eren-
tially expressed between splenic CD8− and CD8+ 
DCs has been identifi  ed (3, 7). Thus, CD8− and 
CD8+ DCs represent genetically and functionally 
distinct DC subsets.
Despite the critical role of DCs in the im-
mune response, the molecular basis of their 
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development, subset specifi  cation, and homeostasis is poorly 
understood. Several important transcriptional regulators of 
hematopoiesis have been shown to control DC development, 
including NF-κB subunits, Ikaros, PU.1, Id2, interferon reg-
ulatory factor (IRF) 8, and STAT3 (for review see reference 8). 
Consistent with their distinct molecular and functional fea-
tures, CD8− and CD8+ DCs are selectively controlled by dif-
ferent transcription factors. For instance, a specifi  c block of 
CD8− DC development was observed in the absence of the 
NF-κB subunit RelB (9) and IRF family members IRF2 (10) 
and IRF4 (11, 12). However, the loss of these and other fac-
tors aff  ects multiple cell types in the immune system and, 
therefore, may infl  uence DCs indirectly. Thus, the DC-
intrinsic roles of transcription factors and major signaling 
pathways remain to be established in vivo, as the task requires 
a system for gene targeting specifi  cally in DCs.
The Notch signaling pathway is an evolutionarily conserved 
mechanism regulating the development of multiple cells and 
tissues (13). Notch signaling involves the interaction at the 
cell surface between Notch receptors and their ligands of the 
Delta and Jagged family, leading to γ-secretase–dependent 
cleavage of Notch. The intracellular domain of Notch 
(NotchIC) translocates into the nucleus, where it interacts 
with a DNA-binding transcription factor CSL (known in the 
mouse as RBP-J or Rbpsuh). The resulting NotchIC–RBP-J 
complex directly activates both general (Hes and Deltex) and 
tissue-specifi  c targets of Notch signaling, thereby aff  ecting 
cellular diff  erentiation and/or homeostasis. In the adaptive 
immune system, Notch signaling is essential for the commit-
ment to and early development of the T cell lineage, gener-
ation of MZ B lymphocytes, and specifi  cation of eff  ector 
T cell functions (for review see reference 14). On the other 
hand, the role of Notch signaling in the cells of the innate 
immune system is poorly understood. Although a potential 
involvement of Notch signaling in the development and/or 
maturation of DCs has been suggested by in vitro studies 
(15–18), the exact function of Notch in the DC lineage 
remains unknown.
In this paper, we have developed a DC-specifi  c Cre del-
eter strain and used it to inactivate RBP-J in the DC lineage 
Figure 1.  Decreased splenic DC content after RBP-J deletion in 
the BM. Control (RBP-Jfl  /fl  ) or CKO (RBP-Jfl  /fl   Mx1-Cre+) mice were in-
jected with poly(I):(C) to induce the deletion of RBP-J in the BM. 3 wk 
later, spleens were analyzed by fl  ow cytometry, and BM was transferred to 
irradiated recipients. (A) Splenic DC compartment in control and CKO 
mice. Shown are the staining profi  les of total splenocytes (or of B220+ 
splenocytes for PDCs), with the fraction of each population in the total 
splenocytes indicated (mean ± SD of three animals). (B) Splenic DC com-
partment in the chimeras established from control or CKO BM. Shown are 
the staining profi  les of donor-derived (CD45.2+) splenocytes 4–5 wk after 
BM transfer, with the fraction of each population in the total donor-
derived splenocytes indicated (mean ± SD of four to six animals). Student’s 
test p-values are indicated for statistically signifi  cant differences.JEM VOL. 204, July 9, 2007  1655
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in vivo. Our results indicate that Notch–RBP-J signaling is 
generally dispensable for DC lineage commitment, yet essen-
tial for DC homeostasis in the spleen. In particular, CD8− 
splenic DCs appear to receive a unique Notch signal that is 
required for their survival and persistence in the MZ. These 
data reveal a role of the Notch–RBP-J pathway in the main-
tenance of the innate immune system.
RESULTS
Decreased splenic DC content after RBP-J deletion 
in the BM
We studied DC development in the absence of RBP-J, an 
essential transcriptional eff  ector of canonical Notch signaling. 
Initially, we used a conditional LoxP-fl  anked RBP-J allele 
(fl  oxed; RBP-Jfl ) in conjunction with an interferon-inducible 
Mx1-Cre transgene, which effi   ciently deletes RBP-J in the 
BM (19). 3 wk after the induction of Cre recombination 
by interferonogen poly(I):(C), conditional knockout (CKO; 
RBP-Jfl / fl  Mx1-Cre+) mice manifested a block of T cell de-
velopment along with increased B cell development in the 
thymus, confi  rming the functional inactivation of Notch 
signaling (Fig. S1 A, available at http://www.jem.org/cgi/
content/full/jem.20062648/DC1). In the spleen, the fractions 
of PDCs and CD11b+ CD11c− monocytes/macrophages were 
elevated; on the other hand, the proportion of conventional 
CD11chigh MHC class II+ DCs was reduced  2.5-fold (Fig. 
1 A). The expression of CD8 in DCs was highly variable in 
this experimental setting, likely because of the nonspecifi  c 
eff  ects of poly(I):(C)-induced interferon response. Nevertheless, 
we noticed a consistent decrease in the fraction of CD11b+ 
DCs corresponding to the CD8− subset.
To confi  rm that the observed DC defect was caused by 
the loss of RBP-J in hematopoietic cells, we reconstituted 
irradiated CD45.1+ mice with the induced CKO or control 
BM (CD45.2+). As expected, RBP-J–defi  cient BM failed to 
generate thymocytes and MZ B cells, whereas it extensively 
contributed to granulopoiesis and follicular B cell develop-
ment (Fig. S1, B–D). Notably, PDC generation from the 
CKO BM was reproducibly enhanced, suggesting an inhibi-
tory role of Notch signaling in PDC development. Impor-
tantly, the proportion of donor-derived splenic DCs was 
reduced in the CKO chimeras to the same extent as in CKO 
donor mice (Fig. 1 B). Because the analysis was performed 
relatively soon after BM transfer (4–5 wk), the distribution of 
CD8− and CD8+ DC subsets could not be fi  rmly established; 
nevertheless, a similar decrease in the fraction of CD11b+ 
DCs was observed in the CKO chimeras. Collectively, these 
results suggest that RBP-J expression in hematopoietic cells 
Figure 2.  DC-specifi  c Cre recombination in the CD11c-Cre deleter 
strain. Shown is the expression of the EYFP reporter gene in the CD11c-
Cre+, R26-EYFP+ mice. Fluorescence profi  les and percentages of EYFP+ 
cells are shown for the indicated cell populations (representative of three 
to fi  ve animals). No EYFP+ cells were detected in the absence of the Cre 
transgene (not depicted). (A) Major splenic cell lineages. (B) DC subsets, 
including splenic PDCs, CD8+ and CD8− DCs, activated DCs in the subcu-
taneous lymph nodes, and splenic DC progenitors. (C) Splenic myeloid 
cells (SSClow CD11b+), divided into four subsets based on Ly-6C and CD11c 
expression levels. Subset IV corresponds to differentiated CD8− DCs. FSC, 
forward scatter; SSC, side scatter.1656  NOTCH CONTROLS DENDRITIC CELL HOMEOSTASIS | Caton et al.
Figure 3.  The loss of splenic CD8− DCs in mice with DC-specifi  c 
RBP-J deletion. Spleens from control (RBP-Jfl  /fl  ) and CKO (RBP-Jfl  /fl   
CD11c-Cre+) mice were analyzed for the indicated cell populations. 
(A) Staining profi  les of PDCs and conventional DCs, with the percentages 
among total splenocytes indicated (mean ± SD of 3 and 17 animals per 
genotype, respectively). Within the DC population, the mean percentages 
of CD8− and CD8+ DC subsets and the CD8−/CD8+ DC ratio are shown. 
(B) Absolute numbers of CD8− and CD8+ DCs in individual control 
(squares) and CKO (triangles) mice. Horizontal lines represent the means. 
(C) Staining of splenic DCs with the CD8− DC–specifi  c mAb 33D1, with 
the fractions of 33D1+ and 33D1− DCs among total splenocytes indi-
cated. A threefold decrease in the absolute number of 33D1+ DCs was 
observed in CKO spleens (not depicted). (D and E) DC populations in the 
cutaneous lymph nodes (D) and the thymus (E). Shown are the staining 
profi  les of lineage-depleted cells, with blood-derived (CD11chigh MHC class II+) 
and mature tissue-derived (CD11c+ MHC class IIhigh) DC populations 
highlighted. The percentages of these populations among the total cells 
of each organ are indicated (mean ± SD of four mice). Within the blood-
derived DC population, the fractions of CD8− and CD8+ subsets are 
shown (mean ± SD of four mice). (F) Staining profi  les of alveolar macro-
phages (CD11chigh MHC class II+) and conventional resident DCs (CD11clow 
MHC class IIhigh) in the lung. The percentage of each population among 
total lung cells is indicated (mean ± SD of four mice).JEM VOL. 204, July 9, 2007  1657
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is required to maintain DC numbers in the spleen and may be 
particularly important in the splenic CD8− DCs.
In contrast to the impaired generation of splenic DCs 
in vivo, DCs and PDCs developed normally in Flt3 ligand–
supplemented cultures of CKO BM (unpublished data). 
Moreover, CD8− DC development from CKO BM in 
GM-CSF–supplemented cultures was accelerated, yield-
ing a signifi  cantly higher proportion of DCs on day 5 (Fig. 
S2 A, available at http://www.jem.org/cgi/content/full/
jem.20062648/DC1). The latter may be caused by the general 
restriction of myeloid cell fates by Notch (20), which is 
relieved in RBP-J–defi  cient BM. Although not statistically 
signifi  cant, a minor reduction of completely matured MHC 
class IIhigh DCs was observed in the CKO cultures by day 10. 
Thus, the Notch–RBP-J pathway appears dispensable for DC 
lineage commitment, suggesting that the decrease in splenic 
DCs in vivo may refl  ect their defective maintenance.
A system for gene targeting specifi  cally in the DC lineage
Because of the pleiotropic eff  ects of Notch signaling in the 
immune system, it was essential to inactivate RBP-J specifi  -
cally in the DC lineage using a DC-specifi  c Cre deleter strain. 
To generate such a strain, we introduced Cre recombinase 
into the CD11c gene within a 160-kb bacterial artifi  cial chro-
mosome (BAC) genomic clone, which was used to generate 
transgenic mice. The resulting CD11c-Cre strain was crossed 
to the Rosa26-StopFlox–enhanced yellow fl  uorescent pro-
tein (R26-EYFP) reporter mice, in which Cre recombina-
tion activates the expression of EYFP from the ubiquitously 
active Rosa26 locus (21). As illustrated in Fig. 2 A, EYFP 
expression was observed in >95% of splenic DCs, compared 
with <10% of lymphocytes and <1% of myeloid cells such as 
granulocytes. The background recombination in lymphocytes 
originated in early lymphoid progenitors in the BM; notably, 
it was not increased in CD11clow-activated T lymphocytes 
(Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.20062648/DC1) (22). Importantly, effi   cient  recombi-
nation was detected in all DC subsets, including CD8− and 
CD8+ DCs, tissue-derived DCs in the lymph nodes, and 
PDCs (Fig. 2 B). In addition, DCs in tissues such as the lung 
and epidermis were mostly EYFP+ (unpublished data). On 
the other hand, CD11clow immediate splenic DC progen-
itors (4) contained only  50% EYFP+ cells, suggesting that 
effi   cient recombination is initiated after DC lineage commit-
ment. Similarly, recombination in GM-CSF–supplemented 
BM cultures followed the emergence of CD11c+ DCs at late 
stages of culture (Fig. S2 B). Furthermore, splenic myeloid cell 
types such as CD11c− monocytes/macrophages were EYFP 
negative, and only partial recombination was observed in 
CD11clow monocytes possibly diff  erentiating into DCs (Fig. 
2 C). The DC compartment in CD11c-Cre+ animals was in-
distinguishable from that of wild-type mice, suggesting that 
Cre expression has no adverse eff  ects on DCs (unpublished 
data). Collectively, these data demonstrate an effi   cient and 
specifi  c recombination in DCs, which is initiated after DC 
lineage commitment and the onset of CD11c expression.
DC-specifi  c RBP-J deletion selectively impairs splenic 
CD8− DCs
To test the cell-intrinsic role of RBP-J in DCs, we generated 
RBP-Jfl / fl  CD11c-Cre+ CKO mice. In these mice, RBP-J 
was completely deleted in DCs but not in macrophages (Fig. 
S4 A, available at http://www.jem.org/cgi/content/full/jem
.20062648/DC1); moreover, normal lymphoid development 
refl  ected the lack of widespread RBP-J deletion (Fig. S4 B). 
On the other hand, the splenic DC population was de-
creased to the same extent as in Mx1-Cre+ CKO mice and 
displayed a signifi  cantly reduced ratio of CD8−/CD8+ DCs 
(Fig. 3 A). This was caused by a threefold decrease in the ab-
solute numbers of CD8− DCs, whereas CD8+ DC numbers 
were unaff  ected (Fig. 3 B). A similar decrease in the propor-
tion of CD8− DCs was observed using the CD8− DC–
specifi  c mAb 33D1 (Fig. 3 C). In contrast, the fractions of 
activated tissue-derived DCs (CD11c+ MHC class IIhigh) and 
of blood-derived DCs (CD11chigh MHC class II+) were nor-
mal in the cutaneous LN, as was the ratio of CD8−/CD8+ 
DCs within the latter population (Fig. 3 D). Similar results 
were obtained in the mesenteric LN (unpublished data). Fur-
thermore, no major abnormalities were observed in the thy-
mic DC population, where blood-derived DCs are largely 
CD8+ (Fig. 3 E). We also analyzed conventional CD11c+ 
resident DCs and DC-like CD11chigh macrophages (23) in 
the lung, as both populations undergo effi   cient Cre recombi-
nation in CD11c-Cre mice. We found that the resident DCs 
in the lung (Fig. 3 F) and in the epidermis (not depicted) 
were largely intact in CKO mice. No enhanced maturation 
(as indicated by increased levels of MHC class II or co-
stimulatory molecules) was observed in CKO DCs, suggesting 
that DC-specifi   c RBP-J deletion does not cause overt 
  infl  ammation. Collectively, these data suggest that splenic 
CD8− DCs are uniquely sensitive to the loss of RBP-J.
To confi  rm the loss of CD8− DCs at the functional level, 
we measured DC cytokine responses to TLR activation by 
fl  ow cytometry. Initially, mice were injected i.v. with TLR 
agonists, resulting in a modest IL-12 expression by a small 
fraction of DCs 2 h later (Fig. 4 A). In this in vivo assay, the 
frequency of IL-12+ DCs was decreased in CKO spleens after 
challenge with the TLR4 agonist LPS and especially with the 
TLR7 agonist imiquimod, which preferentially activates 
CD8− DCs (24, 25). To increase the magnitude of cytokine 
responses by DCs, we analyzed in vitro cultures of splenocytes 
in which the original diff  erences in the DC content were pre-
served. Splenocytes from untreated mice were incubated with 
TLR ligands in vitro for 6 h and stained for intracellular IL-12 
and TNF-α. Although LPS elicited relatively weak cytokine 
responses under these conditions, imiquimod and the TLR9 
agonist unmethylated CpG oligonucleotides (CpG) induced 
the accumulation of IL-12+ and TNF-α+ DCs (Fig. 4 B). 
Notably, the frequency of cytokine-secreting CD8− DCs was 
decreased approximately threefold in CKO cultures, whereas 
the frequency of cytokine-secreting CD8+ DCs was un-
changed (Fig. 4 C). The decrease in cytokine-producing 
CD8− DCs was proportional to their reduced frequency in 1658  NOTCH CONTROLS DENDRITIC CELL HOMEOSTASIS | Caton et al.
Figure 4.  Decreased frequency of cytokine-secreting splenic DCs 
in the absence of RBP-J. (A) The frequency of IL-12–secreting DCs after 
TLR ligand challenge in vivo. Control (RBP-Jfl  /fl  ) and CKO (RBP-Jfl  /fl   CD11c-
Cre+) mice were injected with saline, LPS, or imiquimod, and IL-12 pro-
duction in DCs was detected by intracellular staining. Shown are the 
representative staining profi  les of MHC class II+ splenocytes and the fre-
quency of IL-12+ DCs among total splenocytes (mean ± SD of four to 
fi  ve mice; P < 0.05 for both stimuli). (B and C) The frequency of cytokine-
secreting DCs after TLR ligand challenge in vitro. Lymphoid lineage-
depleted splenocytes were cultured in the presence of the indicated TLR 
ligands, and cytokine production in DCs was detected by intracellular 
staining for IL-12 and TNF-α. Shown are the representative staining pro-
fi  les of CD11chigh MHC class II+ DCs (B) and the frequency of cytokine-
secreting total and CD8− and CD8+ DCs among the splenocytes (C). The 
data represent the mean ± SD of three to four mice per genotype; the 
differences between control and CKO CD8− DCs are statistically signifi  -
cant (P = 0.0002 and P < 0.03 for CpG and imiquimod, respectively).JEM VOL. 204, July 9, 2007  1659
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CKO spleens, suggesting that the loss of RBP-J–defi  cient 
splenic CD8− DCs correlates with defective DC-mediated 
cytokine responses.
Next, we asked whether the depletion of RBP-J–defi  cient 
splenic CD8− DCs might be caused by their impaired lineage 
commitment, proliferation, or survival. The immediate DC 
progenitors, including the CD24− progenitors committed to the 
CD8− DC subset, were unaff  ected in the CKO spleens (Fig. 
5 A). This is consistent with the low recombination frequency 
in the progenitors (Fig. 2 B) and suggests that the depletion 
occurs in mature CD8− DCs after their lineage commitment. 
Indeed, freshly isolated CKO CD8− DCs displayed an in-
creased percentage of apoptotic cells, as measured by staining 
with Annexin V (Fig. 5 B). Furthermore, the rate of BrdU 
incorporation in CKO CD8− DCs was increased, suggesting 
that their faster turnover was caused by decreased survival 
(Fig. 5 C). Collectively, these data suggest that RBP-J regulates 
the maintenance of committed CD8− DCs by facilitating 
their survival. Similarly, the initial DC development in vitro 
from CKO BM was normal, whereas a moderate decrease in 
the fraction of total and mature MHC class IIhigh DCs was 
observed at late stages of culture (Fig. S2 C).
Molecular analysis of the Notch signaling pathway in DCs
To study the molecular basis of Notch signaling in DCs, we 
tested the expression of Notch receptors and target genes by 
quantitative real-time PCR (qPCR). As previously reported (26), 
splenic T and B lymphocytes preferentially expressed Notch1 
and Notch2, respectively, but no detectable Notch4 (Fig. 6). 
On the other hand, wild-type CD8− DCs expressed relatively 
low levels of Notch1 but considerable levels of Notch2 and 
Notch4. The levels of Notch3 were below detection in these 
populations (unpublished data). The expression of at least 
three Notch receptors in DCs raises the possibility of genetic 
redundancy and may explain normal DC development in 
the absence of Notch1 (27). In addition, lymphocytes and 
Figure 5.  Impaired survival and homeostasis of RBP-J–defi  cient 
splenic CD8− DCs. (A) Splenic DC progenitors, including CD24low DC 
progenitors committed to the CD8− subset, in control (RBP-Jfl  /fl  ) and CKO 
(RBP-Jfl  /fl   CD11c-Cre+) mice. The fraction of each subset in the gated pop-
ulation (mean of two animals) is indicated. The fraction of CD24−/low cells 
corresponding to CD8− DC progenitors is indicated by the vertical dotted 
line. (B) The expression of the apoptotic marker phosphatidylserine in 
control and CKO CD8− DCs, as determined by Annexin V staining. Shown 
are the representative profi  les of ex vivo–isolated CD8− DCs stained with 
Annexin V and the dead-cell marker 7-amino-actinomycin D, with the 
fraction of apoptotic cells indicated (mean ± SD of four mice). (C) The 
turnover rate of splenic CD8− DCs. Mice were fed BrdU for 4–5 d, and the 
fraction of BrdU+ CD8− DCs (dotted line) was determined by fl  ow cyto-
metry. Shown are the representative BrdU staining profi  les of gated CD8− 
DCs and the fraction of BrdU+ CD8− DCs in control and CKO mice. 
  Because the effi  ciency of BrdU incorporation and staining varied between 
experiments, control and CKO mice from each experiment were compared 
pairwise and analyzed using the paired Student’s t test.1660  NOTCH CONTROLS DENDRITIC CELL HOMEOSTASIS | Caton et al.
CD8− DCs expressed the canonical Notch–RBP-J target 
genes Hes1 and Deltex1 (Dtx1); notably, the latter was present 
in CD8− DCs but not in monocytes/macrophages (Fig. 6).
We next measured the expression of Notch receptors and 
targets in control and RBP-J–defi  cient CD8− and CD8+ DCs. 
Compared with CD8− DCs, control CD8+ DCs expressed 
higher Notch4 levels but completely lacked Dtx1 expression, 
in agreement with previous microarray data (7). As expected, 
CKO DC subsets showed a complete loss of RBP-J tran-
scripts encoded by deleted exons (Fig. 6). Interestingly, CKO 
CD8− but not CD8+ DCs showed a fourfold reduction in 
Notch4 levels, suggesting that Notch4 expression in CD8− 
DCs is regulated by a positive feedback loop. Although Hes1 
was moderately decreased in both RBP-J–defi  cient DC sub-
sets, the specifi  c expression of Dtx1 in CD8− DCs was com-
pletely abolished in the absence of RBP-J. Therefore, Dtx1 
expression in DCs serves as a faithful indicator of Notch–
RBP-J signaling, and its RBP-J–dependent expression in 
CD8− DCs suggests that they receive a unique Notch signal 
required for their maintenance in the spleen.
To explore a potential source of Notch signals for splenic 
CD8− DCs, we performed immunohistochemical analysis 
using the CD8− DC–specifi  c antibody 33D1. As previously 
described (3), 33D1+ DCs in control spleens were localized 
primarily in the MZ (Fig. 7); moreover, their numbers were 
markedly reduced in CKO spleens, consistent with fl  ow cy-
tometry data (Fig. 3 C). Because Notch ligand Delta-like 1 
(Dll1) was shown to promote DC maturation in vitro (18), 
we analyzed the expression of the Dll1 protein with an anti-
body that revealed its expression in the thymus (28). Notably, 
Dll1 expression was prominent outside of lymphoid follicles, 
including the MZ and possibly the red pulp. Unlike more 
compact DCs, Dll1-expressing cells morphologically resem-
bled stromal cells such as reticular fi  broblasts. Furthermore, 
simultaneous staining revealed a substantial overlap between 
33D1 and Dll1 expression domains in the spleen. Although 
some 33D1+ DCs expressed Dll1 (Fig. 7, bottom, yellow 
cells on merged images), the majority of 33D1+ DCs (green) 
were clearly distinct from Dll1-positive cells (red) but were 
located in close contact with the latter. Thus, Dll1 expressed 
in the splenic MZ stroma is a likely source of Notch signals 
that promote the survival and maintenance of CD8− DCs.
D  I  S  C  U  S  S  I  O  N 
Although Notch signaling is essential for lymphocyte devel-
opment and function, its role in the DC lineage remains 
controversial. For instance, impaired DC generation in vitro 
from Notch1-defi  cient embryonic stem cells and Notch1-
antisense hematopoietic progenitors was previously reported 
(17); in contrast, Notch1-defi  cient BM effi   ciently generated 
all DC subsets in chimeric mice (27). Gain-of-function stud-
ies demonstrated that Notch signaling is generally permissive 
for DC development and may facilitate DC generation and/
or maturation (15, 16, 18). On the other hand, both positive 
(29) and negative (30, 31) eff  ects of Notch signaling on PDC 
development have been reported. These discrepancies may 
refl  ect a potential redundancy of individual Notch receptors, 
nonphysiological eff  ects of induced Notch activation, and/or 
specifi  c features of in vitro systems used. To resolve these 
issues, we took an in vivo loss-of-function approach by in-
activating RBP-J, an essential mediator of signaling by all 
Notch receptors. Indeed, deletion of RBP-J (19, 32) com-
pletely recapitulates the phenotypes of individual receptor 
knockouts (26, 27) and of dominant-negative inhibition of 
Notch signaling (33). Because no Notch-independent func-
tions of RBP-J have been described in the mammalian system 
(13, 14), RBP-J deletion essentially generates a specifi  c block-
ade of the canonical Notch signaling pathway.
Figure 6.  The expression of Notch pathway components in wild-
type and RBP-J–defi  cient DCs. The expression of Notch receptors and 
target genes in splenic DCs was determined by qPCR. Shown are the 
  expression levels of the indicated genes relative to the expression in wild-
type CD8− DCs (indicated by the horizontal dashed line). The lack of signal 
above threshold is indicated by an asterisk. (left) The expression in splenic 
T or B lymphocytes, monocytes/macrophages (M), and CD8− DCs from 
wild-type mice. (right) The expression in CD8− and CD8+ DCs from control 
(RBP-Jfl  /fl  ) and CKO (RBP-Jfl  /fl   CD11c-Cre+) mice. Results represent mean 
relative values ± SD of triplicate qPCR reactions. ND, not determined.JEM VOL. 204, July 9, 2007  1661
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To delete RBP-J in DCs, we used both a broad inducible 
deletion by Mx1-Cre transgene and a constitutive deletion 
specifi  cally in DCs. For the latter purpose, we generated mice 
expressing Cre recombinase under the control of the DC-
specifi  c CD11c locus. Consistent with the faithful recapitula-
tion of gene expression by large BAC-based transgenes, our 
CD11c-Cre transgenic strain mediated effi   cient recombina-
tion primarily in CD11c+ DCs, including CD11clow subsets 
such as PDCs. Because the recombination is initiated in com-
mitted CD11c+ DC progenitors, the system appears suitable 
for the studies of DC homeostasis and function, rather than 
of initial lineage commitment. Importantly, no increase in 
recombination frequency has been observed in activated 
CD11clow T cells, confi  rming the utility of the CD11c-Cre 
strain for functional studies of immune responses. Collec-
tively, the CD11c-Cre strain described in this paper should 
facilitate genetic analysis of cell-intrinsic gene functions in 
DCs in vivo.
Both panhematopoietic and DC-specifi  c deletion of RBP-J 
resulted in the decreased content of splenic DCs, particularly 
of the CD8− DC subset. This DC loss does not appear to re-
fl  ect impaired DC lineage commitment, because (a) RBP-J–
defi  cient BM gave rise to all DC subsets in vivo and in vitro, 
(b) essentially similar phenotypes were caused by RBP-J dele-
tion in the BM hematopoietic progenitors (Mx1-Cre) and in 
committed DCs (CD11c-Cre), and (c) immediate DC pro-
genitors in the spleen were not aff  ected. On the other hand, 
the homeostasis of splenic CD8− DCs was impaired, as indi-
cated by their reduced survival and increased turnover. The 
latter likely refl  ects an increased proliferation of the residual 
CD8− DCs as a compensation for their decreased survival. 
Indeed, splenic DCs undergo in situ proliferation controlled 
by lymphotoxin β receptor (34). Furthermore, a similar in-
crease in BrdU incorporation was observed in DCs from 
CD47−/− mice, in which splenic CD8− DCs are depleted 
because of impaired migration (35). Therefore, Notch–RBP-J 
signaling appears to play a cell-intrinsic role in the mainte-
nance and survival of diff  erentiated DCs, as documented in 
other cell types. For example, Notch signaling is required for 
the metabolic homeostasis and survival of committed T cell 
Figure 7.  Localization of CD8− DCs and Dll1-expressing cells in 
the spleen. (top) Spleen sections from wild-type control (RBP-Jfl  /fl  ) or CKO 
(RBP-Jfl  /fl   CD11c-Cre+) mice were stained for metallophilic macrophages 
delineating the MZ (MOMA-1+; green) and CD8− DCs (33D1; red). A serial 
section of control spleen was stained for MOMA1 (green) and Dll1 (red). 
(middle and bottom) Wild-type spleen sections were stained for CD8− DCs 
(33D1; green) and Dll1 (red). The location of 33D1+ cells in the MZ was 
confi  rmed by MOMA-1 staining of a serial section. Shown are the repre-
sentative individual and merged images of 33D1 and Dll1 staining (mid-
dle) and a high magnifi  cation image of the area indicated by the dashed 
box (bottom). Bars: (top) 400 μm; (middle) 200 μm; (bottom) 100 μm.1662  NOTCH CONTROLS DENDRITIC CELL HOMEOSTASIS | Caton et al.
progenitors (36), and increases the resistance of thymocytes to 
corticosteroid-induced cell death (37).
Although RBP-J deletion in DCs caused the loss of the 
splenic CD8− DC subset, the CD8+ DCs were unaff  ected. 
This selective requirement for Notch–RBP-J signaling in CD8− 
DCs correlated with the specifi  c and RBP-J–dependent ex-
pression of Notch target Dtx1 by this DC population. In 
that respect, CD8− DCs resemble MZ B cells, a splenic 
B lymphocyte population that requires Notch–RBP-J signaling 
and expresses Dtx1 in a Notch-dependent manner (26). Al-
though the requirement for Notch–RBP-J signaling is highly 
specifi  c for CD8− DCs and MZ B cells compared with other 
splenic cell types, the molecular basis of this specifi  city re-
mains to be elucidated. Indeed, neither CD8− DCs (Fig. 6) 
nor MZ B cells (26) express higher levels of Notch receptors 
compared with their Notch-independent counterparts such 
as CD8+ DCs and follicular B cells, respectively. Further-
more, both CD8− and CD8+ DCs appear to receive at least 
some canonical Notch signals, as indicated by reduced Hes1 
expression in both DC types after RBP-J deletion (Fig. 6). 
One possible scenario for the observed specifi  city is the mod-
ulation of Notch ligand–receptor interactions by enzymes 
such as Fringe, which was shown to regulate Notch1 signal-
ing in T cell development (38). Another possible scenario is 
a cell type–specifi  c expression of a transcriptional cofactor for 
RBP-J. For instance, decreased expression of a negative 
RBP-J regulator MINT in MZ B cells facilitates Notch sig-
naling in this subset compared with follicular B cells (39). 
Conversely, a positive Notch–RBP-J signaling cofactor might 
be expressed specifi  cally in CD8− DCs and MZ B cells, a 
possibility that should be explored in future studies.
Another likely determinant of Notch signaling specifi  city 
in CD8− DCs and in MZ B cells is the nature and anatomic 
location of Notch ligands in the spleen. Notably, both cell 
types are located in the MZ, the compartment shown in this 
study to contain Dll1-expressing cells. This Notch ligand ex-
pressed on splenic stromal cells was shown to promote DC 
maturation in vitro, whereas another Notch ligand Jagged-1 
had an inhibitory eff  ect (18). Indeed, we found that CD8− 
DCs in the MZ were residing in close contact with Dll1-
  expressing cells, likely nonhematopoietic stromal cell types 
such as MZ reticular fi  broblasts and/or endothelium of the 
marginal sinus. Moreover, Dll1 deletion in vivo caused the loss 
of MZ B cells (40), suggesting that Dll1 is a critical Notch li-
gand for B cells in the MZ. Therefore, Dll1 is a likely physio-
logical inducer of specifi  c Notch signals that control CD8− DC 
maintenance in the splenic MZ. The unique location of splenic 
CD8− DCs in the MZ is likely to explain their dependence on 
Notch–RBP-J signaling in the spleen but not in other organs 
(Fig. 3). This model is consistent with recent data suggesting a 
unique developmental pathway of splenic DCs compared with 
DCs in other organs (4, 41). Because CD8+ DCs were also 
detected in the MZ (5), further studies are required to clarify 
whether CD8+ DCs receive similar Notch signals. Collec-
tively, our studies suggest that splenic MZ is an important 
source of Notch signals for both MZ B cells and CD8− DCs.
 In conclusion, we report an unexpected role of Notch 
signaling in the homeostasis of splenic DCs. These results 
emphasize the critical role of Notch pathway not only in 
lymphocyte development and diff  erentiation but also in the 
maintenance of the innate immune system. Notably, the loss 
of RBP-J–defi  cient splenic CD8− DCs was mirrored by the 
decreased frequency of cytokine-secreting DCs during chal-
lenge with TLR agonists. From the practical standpoint, these 
results suggest that γ-secretase inhibitors may aff  ect DC-
mediated responses when administered in vivo. This possibility 
further supports the utility of these agents as immunosuppres-
sors (42) and broadens the spectrum of their potential cellular 
targets. For instance, the reported benefi  cial eff  ects of γ-secre-
tase inhibitors in experimental autoimmunity (42) might re-
sult from the combined modulation of T cell and DC function 
by these drugs. Further studies are required to elucidate 
Notch-mediated control of DC function in the steady state 
and during immune responses.
MATERIALS AND METHODS
Mice. To generate the CD11c-Cre transgene, the 160-kb mouse genomic 
BAC clone RP24-361C4 (BACPAC Resources) was modifi  ed by ET 
recombination, as previously described (43). The clone contains the entire 
Itgax (CD11c) gene but lacks the 5′ end of the adjacent Itgam (CD11b) gene, 
preventing the overexpression of the latter. The recombination cassette con-
taining the Cre recombinase open reading frame, followed by the bovine 
growth hormone (BGH) polyA signal and the FRT site-fl  anked prokaryotic 
Zeocin resistance cassette (ZeoR), replaced the coding part of the fi  rst CD11c 
exon, and the ZeoR cassette was subsequently removed by FLP-mediated 
recombination. The clone insert was released from the vector backbone us-
ing NotI digestion, gel-purifi  ed, and microinjected into fertilized oocytes. 
The founder line containing two copies of the transgene (as determined by 
quantitative Southern hybridization) was chosen for further analysis. Mice 
were genotyped by genomic PCR using either generic Cre primers or prim-
ers specifi  c for the CD11c-Cre transgene (5′-A  C  T  T  G  G  C  A  G  C  T  G  T  C  T  C  C-
A  A  G  -3′ and 5′-G  C  G  A  A  C  A  T  C  T  T  C  A  G  G  T  T  C  T  G  -3′ were specifi  c for the 
CD11c promoter and Cre, respectively).
The R26-EYFP strain (21) was provided by F. Costantini (Columbia 
University, New York, NY). The RBP-Jfl  strain (19) was provided by L. 
Hennighausen (National Institute of Diabetes and Digestive and Kidney 
Diseases, Bethesda, MD), with permission from T. Honjo (Kyoto Univer-
sity, Kyoto, Japan). The Mx1-Cre strain was previously described (44). Cre-
negative RBP-Jfl / fl  littermates of CKO (RBP-Jfl / fl  Cre+) mice were used as 
controls; in preliminary experiments, wild-type CD11c-Cre+ mice were 
used as controls and were found indistinguishable from CD11c-Cre− ani-
mals. For inducible RBP-J deletion, adult RBP-Jfl / fl  Mx1-Cre+ or control 
RBP-Jfl / fl  mice were injected with 0.25 mg poly(I):(C) three times, with 2-d 
intervals, and analyzed 3 wk later. For hematopoietic reconstitution, 3 × 106 
total BM cells per mouse were injected i.v. into lethally irradiated C57BL/6 
mice congenic for CD45.1. The recipient mice were analyzed 4–5 wk after 
reconstitution. Mice were maintained in a specifi  c pathogen-free facility and 
used according to the protocol approved by the Columbia University’s 
Institutional Animal Care and Use Committee.
Flow cytometry. Lymphoid organs and lungs were digested for 1 h at 37°C 
with collagenase D (Roche) in DMEM/10% FCS, fi  ltered, and subjected to 
red blood cell lysis. Single-cell suspensions were stained with fl  uorochrome- 
or biotin-conjugated antibodies (obtained from eBioscience, BD Bio-
sciences, or Miltenyi Biotec), followed by streptavidin conjugate for four to 
fi  ve color analysis. Where indicated in the fi  gures, the lymphoid lineage 
(CD19/CD3/DX5)–negative cell fraction was isolated using magnetic beads 
(Miltenyi Biotec). The immediate DC progenitors were defi  ned as previously JEM VOL. 204, July 9, 2007  1663
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described (4), except that the nonessential signal regulatory protein α stain-
ing was omitted. For the analysis of BrdU incorporation, mice were injected 
with 1 mg BrdU i.p. and kept on 0.8 mg/ml BrdU-supplemented water for 
4–5 d, and splenocytes were stained for cell surface markers and BrdU using 
the BrdU Flow Kit (BD Biosciences). For apoptosis detection, cells were 
stained with antibody conjugates, FITC-conjugated Annexin V (TACS 
reagent; Trevigen, Inc.), and 7-amino-actinomycin D. The samples were 
acquired using a fl  ow cytometer (LSR II; BD Biosciences) or sorted on a 
fl  ow sorter (FACSAria; BD Biosciences) and analyzed using FlowJo software 
(TreeStar, Inc.). Unless indicated otherwise in the fi  gures, cells were gated 
on the side scatter–low lymphoid population; light scatter and fl  uorescence 
are displayed on a linear and log10 scale, respectively.
Challenge with TLR ligands. For in vivo assays, mice were injected i.v. 
with 10 μg LPS (Sigma Aldrich), 200 μg imiquimod (Invivogen), or saline 
and killed 2 h later. Splenocytes were collagenase-treated and incubated in 
DMEM/10% FCS for 3 h in the presence of 10 μg/ml brefeldin A (Sigma-
Aldrich), stained for surface markers, fi  xed, permeabilized, and stained with 
Allophycocyanin (APC)-conjugated anti–mouse IL-12 or an isotype control 
(BD Biosciences). For in vitro assays, splenocytes from untreated mice were 
enriched for a lineage-negative fraction and plated at 106 cells/well in 
96-well round–bottom plates. Cells were treated with saline, 1 μg/ml LPS, 
100 nM CpG (Invivogen), or 3 μg/ml imiquimod for 2 h and incubated for 
an additional 4 h in the presence of TLR ligands and brefeldin A. Cells were 
stained for surface markers, fi  xed, permeabilized, and stained with APC-
conjugated anti–mouse IL-12, anti–mouse TNF-α, or isotype controls.
Expression analysis. Total RNA isolated from ex vivo–sorted cells was re-
verse transcribed and assayed by qPCR on an instrument (MX3000P; Strata-
gene) using SYBR green incorporation. All genes were normalized to 
β-actin, and relative expression was calculated using the ∆∆CT method. All 
primer pairs spanned introns and were validated for amplifi  cation effi   ciency.
Immunochemistry. Spleens were frozen, and 5-μm cryostat sections were 
fi  xed in acetone, blocked in 3% BSA, and stained with FITC-conjugated 
antimetallophilic macrophages (MOMA-1; Serotec) and biotin-conjugated 
anti–DC inhibitory receptor 2 (33D1; eBioscience), followed by Alexa Fluor 
488– or Alexa Fluor 568–conjugated streptavidin (Invitrogen), or polyclonal 
goat anti–mouse Dll1 (SC-9932; Santa Cruz Biotechnology, Inc.), followed 
by Alexa Fluor 568–conjugated anti–goat IgG (Invitrogen). Images were 
obtained on a microscope (model IX71; Olympus) equipped with a mono-
chrome camera (model C8484; Hamamatsu) and processed using Micro  Suite 
software (Olympus).
Statistical analysis. Unless indicated otherwise, data were analyzed using 
the two-tailed, unpaired Student’s t test.
Online supplemental material Fig. S1 shows lymphocyte development 
after RBP-J deletion in Mx1-Cre CKO mice. Fig. S2 depicts in vitro DC 
development in the absence of RBP-J. Fig. S3 shows Cre recombination 
in activated T cells from CD11c-Cre mice. Fig. S4 depicts the specifi  city 
of RBP-J deletion mediated by the CD11c-Cre transgene. Online supple-
mental material is available at http://www.jem.org/cgi/content/full/jem
.20062648/DC1.
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